Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: GLSI-100

Sponsor

Greenwich LifeSciences, Inc.